.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AF07_Deucravacitinib.Deucravacitinib

Information

Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor used for the treatment of moderate-to-severe plaque psoriasis in adults. It is approved and commercially available in several countries for this indication.

Pharmacokinetics

Pharmacokinetic parameters derived from healthy adult volunteers after single and repeated oral administration.

References

1. Jing, S, et al., & Aras, U (2023). Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects. Dermatology and therapy 13(12) 3153–3164. DOI:10.1007/s13555-023-01050-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37981596

2. Greenzaid, J, & Feldman, S (2024). Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis. Clinical pharmacokinetics 63(2) 137–153. DOI:10.1007/s40262-023-01341-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38280146

3. Chen, X, & Lin, Z (2025). A Physiologically Based Pharmacokinetic Model of an Oral Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Adults. Journal of clinical pharmacology None –. DOI:10.1002/jcph.70014 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40029105

Revisions

• 06/2025 initial generated model